Lyme Disease

Disclaimer: > [!WARNING] Medical Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Medical guidelines and best practices change rapidly; users should verify information with current local protocols.

1. Overview

Lyme Disease (Lyme borreliosis) is a multi-system bacterial infection caused by the spirochaete Borrelia burgdorferi sensu lato complex, transmitted through the bite of infected Ixodes ticks. [1,2] It is the most common vector-borne disease in the Northern Hemisphere, with over 300,000 cases estimated annually in the United States alone and increasing incidence across Europe and Asia. [3]

The disease presents a significant diagnostic and therapeutic challenge due to its protean manifestations across multiple organ systems and its ability to mimic numerous other conditions. Early recognition and treatment are crucial, as delayed diagnosis can lead to serious neurological, cardiac, and rheumatological complications. [4]

Like syphilis (another spirochaetal infection), Lyme disease progresses through distinct clinical stages and has earned the moniker "the great imitator" due to its diverse presentations, which can resemble conditions ranging from fibromyalgia to multiple sclerosis in later stages. [5]

Clinical Importance

Lyme disease is clinically significant for several reasons:

High and Increasing Incidence: Cases have increased by over 300% in endemic regions over the past two decades, driven by climate change, reforestation, and increased outdoor recreational activities. [3]

Multi-System Involvement: Untreated infection can disseminate to skin, nervous system, heart, and joints, causing significant morbidity and disability. [6]

Diagnostic Challenges: The two-tier serological testing system has limitations in early disease, leading to both false negatives in early infection and false positives in low-prevalence populations. [7]

Long-Term Sequelae: A subset of patients experience persistent symptoms after treatment (Post-Treatment Lyme Disease Syndrome), though the mechanisms remain poorly understood. [8]

---

2. Epidemiology

Geographic Distribution

Lyme disease occurs across temperate regions of the Northern Hemisphere where competent Ixodes tick vectors are present. [3,9]

Temporal Patterns

Peak transmission occurs during late spring and summer (May-September) when nymphal ticks are most active. [3,9] Nymphal Ixodes ticks (1-2mm, poppy seed size) are responsible for the majority of human infections due to their small size and greater difficulty of detection compared to adult ticks.

Demographics

Age Distribution: Bimodal pattern with peaks in children aged 5-9 years and adults aged 55-70 years, reflecting outdoor exposure patterns. [11]

Sex: Males are affected slightly more than females (1.2:1 ratio), likely due to occupational and recreational exposure differences. [11]

Occupational Risk: Forestry workers, military personnel, outdoor recreation workers, and landscapers have significantly elevated risk. [9]

Vector Biology and Transmission

Tick Attachment Duration: Transmission of B. burgdorferi requires 24-48 hours of tick attachment in most cases, though transmission can occur sooner if the tick has partially fed previously. [12]

Reservoir Hosts: White-footed mice (Peromyscus leucopus) in North America and various rodent species in Europe serve as primary reservoir hosts. Deer serve as reproductive hosts for adult ticks but are not competent reservoirs for Borrelia. [9]

Tick Lifecycle: Ixodes ticks have a two-year lifecycle with larval, nymphal, and adult stages. Larvae typically acquire infection from infected reservoir hosts during their first blood meal. [12]

---

3. Aetiology & Pathophysiology

Causative Organisms

Lyme disease is caused by bacteria within the Borrelia burgdorferi sensu lato complex. The genospecies varies by geographic region and influences clinical manifestations: [1,2]

North America:

• B. burgdorferi sensu stricto (predominant)

Europe:

• B. afzelii (associated with acrodermatitis chronica atrophicans)
• B. garinii (associated with neuroborreliosis)
• B. burgdorferi sensu stricto

Asia:

• B. afzelii
• B. garinii
• B. japonica

Molecular Pathogenesis

Exam Detail: Initial Inoculation and Local Infection:

When an infected Ixodes tick feeds, Borrelia spirochetes are transmitted via tick saliva into the dermis. The bacteria express outer surface protein A (OspA) while in the tick midgut but downregulate OspA and upregulate OspC during transmission, facilitating mammalian infection. [13]

Immune Evasion Mechanisms:

B. burgdorferi employs multiple sophisticated strategies to evade host immune responses:

1. Antigenic Variation: The VlsE (variable major protein-like sequence, expressed) system generates extensive surface protein diversity through recombination, allowing evasion of adaptive immunity. [13]

2. Complement Resistance: The bacteria bind host complement regulators (Factor H, FHL-1) to prevent complement-mediated lysis. [13]

3. Biofilm Formation: Borrelia can aggregate into biofilm-like structures in tissues, potentially contributing to antibiotic tolerance and persistent symptoms in some cases. [14]

4. Slow Growth: Doubling time of 12-24 hours (compared to 20-30 minutes for E. coli) may contribute to the prolonged antibiotic courses required for cure. [1]

Local Spread and Erythema Migrans:

Following inoculation, spirochetes migrate centrifugally through the dermis via extracellular matrix degradation (mediated by bacterial proteases and host matrix metalloproteinases). This centrifugal spread creates the characteristic expanding erythema migrans rash. [1,13]

The inflammatory response involves recruitment of neutrophils, macrophages, and dendritic cells, with production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-8). However, Borrelia actively suppresses Th1 responses that would facilitate bacterial clearance. [13]

Haematogenous Dissemination:

If untreated, Borrelia disseminates via blood and lymphatics to distant sites, particularly tissues with abundant extracellular matrix: [1,6]

• Nervous System: Meninges, cranial nerves (especially VII), nerve roots, peripheral nerves
• Cardiovascular System: Myocardium (especially AV node conduction tissue), pericardium
• Musculoskeletal System: Synovium, tendons, bursae
• Skin: Disseminated erythema migrans lesions

Neuroborreliosis:

In the nervous system, spirochetes cross the blood-brain barrier via direct traversal and/or through infected immune cells. Infection triggers intense lymphocytic inflammation in meninges and nerve roots. The facial nerve is particularly susceptible due to its anatomical passage through the narrow facial canal, where inflammation causes compression and palsy. [15]

Lyme Carditis:

Cardiac involvement occurs in approximately 1% of cases. Spirochetes directly invade myocardial tissue, particularly the AV node region, triggering lymphocytic and plasma cell infiltration. This inflammation disrupts cardiac conduction, manifesting as AV blocks of varying degrees (first-degree to complete heart block). [6,16]

Lyme Arthritis:

Arthritis typically manifests months after initial infection. Spirochetes trigger intense synovial inflammation with infiltration of neutrophils, macrophages, and T cells. In some patients, particularly those with HLA-DR4 alleles, autoimmune mechanisms may perpetuate inflammation even after bacterial clearance, leading to antibiotic-refractory arthritis. [17]

Host Immune Response

The host mounts both innate and adaptive immune responses:

Innate Immunity: TLR2 recognition of Borrelia lipoproteins triggers NF-κB activation and inflammatory cytokine production. [13]

Adaptive Immunity: B and T cell responses develop over weeks to months. IgM antibodies appear first (3-6 weeks), followed by IgG (6-8 weeks). However, antibody responses are often inadequate to clear infection without antibiotic treatment. [7]

---

4. Clinical Presentation

Lyme disease progresses through three distinct clinical stages, though not all patients progress through all stages, and stages can overlap. [4,5]

Stage 1: Early Localized Disease (3-30 days post-tick bite)

Erythema Migrans (EM):

• Present in 70-80% of patients [4]
• Appears 3-30 days (median 7 days) after tick bite
• Begins as small red macule or papule at bite site
• Expands centrifugally at rate of ~2cm/day
• Typical size: 5-30cm diameter (median 15cm)
• Classic morphology: annular erythema with central clearing ("bull's-eye" or "target" lesion)
• Variations: homogenous erythema, vesicular center, central necrosis
• Usually non-pruritic and minimally tender
• Warm to touch but not hot
• May have central induration
• Fades over 3-4 weeks even without treatment

Multiple Erythema Migrans: 10-20% of patients develop multiple secondary EM lesions due to early haematogenous dissemination, indicating more severe infection. [4]

Systemic Symptoms:

• Fatigue (80%)
• Headache (64%)
• Myalgia (61%)
• Arthralgia (51%)
• Low-grade fever (39%)
• Neck stiffness (35%)
• Lymphadenopathy (regional or generalized)

Stage 2: Early Disseminated Disease (Weeks to Months)

Neurological Manifestations (10-15% of untreated cases) [15]

Classic Triad of Neuroborreliosis:

1. Lymphocytic meningitis: Headache, neck stiffness, photophobia
2. Cranial neuropathy: Facial nerve palsy (most common)
3. Radiculoneuritis: Painful radiculopathy (Bannwarth syndrome in Europe)

Facial Nerve Palsy:

• Most common cranial neuropathy in Lyme disease
• Bilateral in 25-30% of cases (highly suggestive of Lyme etiology when in endemic area)
• Unilateral presentation clinically identical to Bell's palsy
• Recovery typically occurs over 2-3 months

Bannwarth Syndrome (more common in Europe):

• Severe radicular pain, often nocturnal
• Asymmetric or patchy limb weakness
• CSF pleocytosis with elevated protein
• May involve multiple nerve roots

Other Neurological Features:

• Meningitis with lymphocytic pleocytosis
• Cranial nerve VI, III involvement
• Peripheral neuropathy
• Mononeuritis multiplex
• Encephalomyelitis (rare)

Cardiac Manifestations (0.3-1% of cases) [6,16]

Lyme Carditis:

• AV conduction abnormalities (most common):
  • First-degree AV block (48%)
  • Second-degree AV block (16%)
  • Complete heart block (36%)
  • Can fluctuate rapidly between degrees
• Myopericarditis (less common)
• Left ventricular dysfunction (rare)
• Sudden cardiac death (extremely rare)

Clinical Features:

• Palpitations
• Presyncope or syncope
• Dyspnoea
• Chest pain
• May occur without preceding EM rash in 30-50%

Rheumatological Manifestations

Early Arthralgia:

• Migratory musculoskeletal pain
• Often preceding frank arthritis by weeks to months
• No objective joint swelling

Borrelial Lymphocytoma:

• Rare bluish-red nodular infiltrate
• Predilection for earlobes, nipples, scrotum
• More common in children
• More common in Europe

Stage 3: Late Disseminated Disease (Months to Years)

Lyme Arthritis (60% of untreated North American cases) [17]

Characteristics:

• Begins months (range: 2 weeks to 2 years) after initial infection
• Intermittent, migratory oligoarthritis
• Large joints preferentially affected (especially knee - 90% of cases)
• Episodes last weeks to months
• Large effusions common (often > 50mL)
• Joint aspiration: inflammatory fluid (10,000-25,000 WBC/μL, predominantly neutrophils)
• Synovial biopsy: villous hypertrophy, vascular proliferation, lymphocytic infiltrate
• Radiographs: usually normal initially; chronic cases may show cartilage loss

Antibiotic-Refractory Lyme Arthritis:

• Persists despite adequate antibiotic therapy in ~10% of cases
• Associated with HLA-DR4 and HLA-DRB1*0401 alleles
• Thought to represent autoimmune phenomenon
• Responds to disease-modifying antirheumatic drugs (DMARDs)

Neurological Manifestations

Late Neuroborreliosis:

• Chronic encephalomyelopathy (rare)
• Peripheral neuropathy (subtle, often sensory)
• Cognitive impairment ("brain fog")
• Sleep disturbance
• Mood changes

Encephalopathy:

• Subtle cognitive difficulties
• Memory impairment
• Processing speed reduction
• Mood disturbance
• Objective findings on neuropsychological testing
• MRI may show non-specific white matter changes

Dermatological Manifestations

Acrodermatitis Chronica Atrophicans (ACA):

• Chronic, progressive skin condition
• Almost exclusively European (associated with B. afzelii)
• Rare in North America
• Affects extensor surfaces of limbs
• Initial phase: bluish-red discoloration and edema
• Late phase: atrophic, paper-thin skin
• May have associated peripheral neuropathy

---

5. Differential Diagnosis

Lyme disease's protean manifestations necessitate consideration of multiple differential diagnoses based on the stage and system involved. [5]

Erythema Migrans Differential

Neurological Lyme Differential

Cardiac Lyme Differential

Lyme Arthritis Differential

---

6. Investigations

The diagnosis of Lyme disease is primarily clinical in the presence of erythema migrans in an endemic area. Laboratory testing supports diagnosis in disseminated disease without EM. [4,7]

Clinical Diagnosis (No Laboratory Testing Required)

Erythema Migrans in endemic area = Lyme disease (specificity > 95%)

• Treat empirically; do NOT delay for serology
• Document: size, morphology, location, photograph
• Serology often negative in early disease (antibodies require 4-8 weeks to develop)

Serological Testing: Two-Tier Algorithm [7,18]

Indications:

• Suspected disseminated Lyme disease without EM
• Neurological symptoms in endemic area
• Arthritis in endemic area
• Carditis in young patient without other cause

First-Tier Test: Enzyme Immunoassay (EIA/ELISA)

Modern assays use C6 peptide or VlsE antigens with improved sensitivity and specificity compared to older whole-cell lysate assays. [18]

• Sensitivity:
  • "Early localized disease (EM): 40-60%"
  • "Early disseminated disease: 70-90%"
  • "Late disease: > 95%"
• Specificity: 95-98%
• If negative: Lyme disease unlikely (unless tested very early)
• If positive or equivocal: Proceed to second-tier testing

Second-Tier Test: Immunoblot (Western Blot)

Confirms positive or equivocal EIA results. [7,18]

IgM Immunoblot (positive if ≥2 of 3 bands):

• 23 kDa (OspC)
• 39 kDa (BmpA)
• 41 kDa (Fla)

IgG Immunoblot (positive if ≥5 of 10 bands):

• 18, 23, 28, 30, 39, 41, 45, 58, 66, 93 kDa

Interpretation Principles:

• IgM appears at 3-6 weeks, peaks at 6-8 weeks
• IgG appears at 6-8 weeks, persists for years
• IgM alone positive beyond 4 weeks of symptoms: Consider false positive
• IgG positive: Indicates current or past infection; cannot distinguish active from prior treated infection
• After treatment: Antibodies persist for years; serology cannot be used to assess cure
• Seronegative Lyme disease: Rare; consider if high clinical suspicion and alternative diagnoses excluded

Modified Two-Tier Testing (MTTT) [18]

Recent evidence supports alternative two-EIA approach:

• First EIA (C6 or whole-cell lysate)
• If positive: Second EIA with different antigen set
• Eliminates need for Western blot
• Equal or better sensitivity and specificity
• Faster turnaround time
• Approved by CDC as alternative to traditional two-tier testing

Pitfalls in Serological Testing [7,18]

False Negatives:

• Early infection (insufficient time for antibody development)
• Immunosuppressed patients
• Prompt antibiotic treatment (may blunt antibody response)

False Positives:

• Cross-reactivity with other spirochetes (syphilis, leptospirosis, relapsing fever)
• Epstein-Barr virus infection
• Autoimmune diseases (especially SLE, RA)
• Periodontal disease
• Low pretest probability populations

Key Principle: Do not screen asymptomatic patients or low-probability cases; positive predictive value is low when pretest probability is low.

Neuroborreliosis Investigations [15]

Cerebrospinal Fluid Analysis:

• Indications: Suspected CNS Lyme disease (meningitis, encephalitis, radiculitis)
• Findings:
  • Lymphocytic pleocytosis (50-300 cells/μL, predominantly mononuclear)
  • Elevated protein (0.5-2.0 g/L)
  • Normal or mildly decreased glucose
  • "Intrathecal antibody production (elevated CSF:serum antibody index)"
  • "B. burgdorferi PCR: low sensitivity (10-30%); positive result confirms diagnosis but negative does not exclude"

Diagnostic Criteria for Definite Neuroborreliosis:

1. Neurological symptoms consistent with neuroborreliosis
2. CSF pleocytosis
3. Intrathecal Borrelia-specific antibody production

Lyme Carditis Investigations [6,16]

Electrocardiogram:

• Essential in all suspected cases
• May show:
  • PR prolongation (first-degree AV block)
  • Mobitz I or II (second-degree AV block)
  • Complete heart block
  • Conduction abnormalities can fluctuate rapidly; serial ECGs recommended

Echocardiography:

• Usually normal
• May show reduced ejection fraction if myocarditis present
• Rule out structural causes of conduction disease

Cardiac Biomarkers:

• Troponin may be mildly elevated
• BNP may be elevated if heart failure present

Endomyocardial Biopsy:

• Rarely performed
• Shows lymphocytic infiltrate
• PCR may detect Borrelia DNA

Lyme Arthritis Investigations [17]

Synovial Fluid Analysis:

• Cell count: 10,000-25,000 WBC/μL (range: 500-110,000)
• Differential: Predominantly neutrophils (60-80%)
• Culture: Sterile (excludes septic arthritis)
• PCR for B. burgdorferi DNA: Positive in ~70% of untreated cases; more sensitive than culture

Synovial Biopsy:

• Not routinely needed
• Shows villous hypertrophy, vascular proliferation, lymphocytic infiltrate
• Similar to rheumatoid arthritis histologically

Imaging:

• Radiographs: Often normal early; chronic cases may show joint space narrowing, cartilage loss
• MRI: Large effusion, synovial hypertrophy, no erosions (unlike RA)
• Ultrasound: Effusion, synovial thickening

---

7. Management

Management of Lyme disease is stage-specific and based on organ system involvement. Early treatment prevents progression to disseminated disease. [4,19]

General Principles

1. Early localized disease with EM: Treat empirically; do NOT wait for serology
2. Oral antibiotics: First-line for most manifestations
3. Intravenous antibiotics: Reserved for neurological or severe cardiac disease
4. Duration: Typically 10-28 days depending on manifestation
5. Follow-up: Clinical assessment; serology not useful for assessing cure

Early Localized Disease (Erythema Migrans) [4,19]

First-Line:

• Doxycycline 100mg PO BD for 10-21 days
  • Most effective agent
  • Also covers Anaplasma (co-transmitted tick-borne pathogen)
  • Preferred in adults and children ≥8 years

Alternatives (if doxycycline contraindicated):

• Amoxicillin 500mg PO TDS for 14-21 days
  • Pregnancy, children less than 8 years
• Cefuroxime axetil 500mg PO BD for 14-21 days
• Azithromycin 500mg PO OD for 7-10 days
  • Less effective than above options; use only if others contraindicated
  • Higher failure rates (84% vs 100% cure rates)

Duration Note: IDSA guidelines recommend 10 days for uncomplicated EM; European guidelines recommend 14-21 days. Most experts favor 14-21 days. [19,20]

Multiple Erythema Migrans [4,19]

• Same regimens as single EM
• Longer duration recommended: 21 days
• Indicates haematogenous dissemination

Early Neurological Disease (Neuroborreliosis) [15,19,20]

Cranial Neuropathy (Facial Palsy) Without Meningitis:

• Oral therapy:
  • Doxycycline 100mg PO BD for 14-28 days
  • Amoxicillin 500mg PO TDS for 14-28 days

Meningitis or Radiculoneuritis:

• Preferred:
  • Ceftriaxone 2g IV OD for 14-28 days
  • Excellent CSF penetration
• Alternative:
  • Cefotaxime 2g IV TDS for 14-28 days
  • Penicillin G 18-24 million units/day IV (divided q4h) for 14-28 days
  • Doxycycline 200mg PO BD for 14-28 days
    • Recent evidence suggests oral doxycycline may be as effective as IV ceftriaxone for European Lyme neuroborreliosis [20]
    • Less well-studied in North American disease

Duration: Minimum 14 days; extend to 21-28 days for more severe disease or slow response

Adjunctive Treatment:

• Corticosteroids: NOT routinely recommended for facial palsy in Lyme disease (unlike Bell's palsy)
• Eye protection: If incomplete eye closure (lubricating drops, eye patch at night)

Cardiac Disease (Lyme Carditis) [6,16,19]

Admission and Monitoring:

• First-degree AV block (PR > 300ms): Consider admission for monitoring
• Second or third-degree AV block: Admit to telemetry; consider ICU
• Symptomatic bradycardia/syncope: Admission mandatory

Antibiotic Therapy:

• High-degree AV block or symptomatic:
  • Ceftriaxone 2g IV OD for 14-28 days
  • Switch to oral when AV block resolves (usually within 1 week)
• First-degree AV block, asymptomatic:
  • Doxycycline 100mg PO BD for 14-21 days (outpatient acceptable with close follow-up)

Temporary Pacing:

• Indications: symptomatic bradycardia, complete heart block with slow ventricular escape
• Usually needed for 3-7 days; conduction recovers rapidly with antibiotics
• Permanent pacemaker almost never required

Monitoring:

• Daily ECGs until resolution
• Conduction abnormalities can fluctuate rapidly

Lyme Arthritis [17,19]

First-Line:

• Doxycycline 100mg PO BD for 28 days
• Amoxicillin 500mg PO TDS for 28 days
• Cefuroxime axetil 500mg PO BD for 28 days

Note: Oral antibiotics as effective as IV for Lyme arthritis; IV NOT indicated unless neurological involvement

Repeat Course:

• If arthritis persists after 28 days, consider second 28-day course
• Only ONE repeat course recommended; further antibiotics unlikely to help if two courses ineffective

Antibiotic-Refractory Lyme Arthritis (persistent after two 28-day courses):

• Defined as persistent arthritis despite adequate antibiotic therapy
• Thought to represent post-infectious autoimmune phenomenon
• Management:
  • NSAIDs
  • Intra-articular corticosteroid injection
  • "Disease-modifying antirheumatic drugs (DMARDs):"
    • Hydroxychloroquine
    • Methotrexate
  • Arthroscopic synovectomy if refractory to DMARDs

Late Neurological Disease [15,19]

Chronic Encephalopathy or Polyneuropathy:

• Ceftriaxone 2g IV OD for 14-28 days
• Evidence for benefit is limited; response may be slow and incomplete

Special Populations

Pregnancy [19]:

• Early disease: Amoxicillin 500mg PO TDS for 14-21 days
• Neuroborreliosis/carditis: Ceftriaxone 2g IV OD for 14-28 days
• Avoid doxycycline (tooth discoloration, bone growth inhibition)
• Vertical transmission described but rare
• No evidence of congenital anomalies from treated maternal Lyme disease

Children [19]:

• Age less than 8 years: Amoxicillin preferred (avoid doxycycline due to tooth staining)
• Age ≥8 years: Doxycycline acceptable (tooth staining risk minimal after age 8)
• Dosing:
  • "Amoxicillin: 50mg/kg/day divided TDS (max 500mg TDS)"
  • "Doxycycline: 4mg/kg/day divided BD (max 100mg BD)"
  • "Ceftriaxone: 50-75mg/kg/day IV OD (max 2g OD)"

Renal Impairment:

• Doxycycline: No dose adjustment needed (non-renal clearance)
• Ceftriaxone: No adjustment needed for mild-moderate impairment; consider dose reduction in severe impairment

Hepatic Impairment:

• Doxycycline: Use with caution; may worsen hepatic dysfunction
• Ceftriaxone: Monitor; high biliary excretion

Jarisch-Herxheimer Reaction [19]

• Occurs in 7-30% of patients within 24 hours of starting antibiotics
• Fever, chills, rigors, headache, myalgia, hypotension
• Caused by release of bacterial lipoproteins triggering cytokine release
• Self-limited; resolves within 24-48 hours
• Management: supportive care, antipyretics
• Critical: Warn patients in advance; reassure this does NOT represent treatment failure or allergy

Post-Treatment Lyme Disease Syndrome (PTLDS) [8,19]

Definition: Persistent subjective symptoms (fatigue, musculoskeletal pain, cognitive complaints) for > 6 months after completion of appropriate antibiotic therapy for confirmed Lyme disease.

Prevalence: 10-20% of treated patients

Pathophysiology: Unknown; proposed mechanisms include:

• Residual tissue damage from infection
• Post-infectious autoimmune phenomenon
• Dysregulation of immune/inflammatory pathways
• Neuroplastic changes

Diagnosis of Exclusion: Must rule out:

• Relapse/re-infection (uncommon)
• Co-infection (Babesia, Anaplasma, etc.)
• Alternative diagnosis
• Complications of Lyme disease

Management:

• NOT chronic active infection: No evidence of persistent viable Borrelia despite symptoms
• Prolonged antibiotics NOT recommended: Multiple high-quality RCTs show NO benefit and significant harm (adverse effects, C. difficile, antibiotic resistance) [8,19]
• Supportive care:
  • Symptomatic treatment (analgesics, sleep hygiene)
  • Graded exercise therapy
  • Cognitive-behavioural therapy
  • Multidisciplinary rehabilitation if severely affected
• Prognosis: Most patients improve gradually over 6-12 months

"Chronic Lyme Disease" Controversy [8,19]

Important Distinction: "Chronic Lyme disease" as used in popular media/alternative medicine is NOT the same as PTLDS or late Lyme disease.

Scientific Consensus (IDSA, AAN, ACR): [19]

• No evidence for chronic persistent Borrelia infection in patients with PTLDS
• No evidence for benefit of prolonged antibiotic therapy (> 1 month)
• Significant harms from prolonged antibiotics documented

Beware: Alternative providers offering:

• Long-term IV antibiotics (months to years)
• Diagnoses based on unvalidated tests
• Claims that all tests are "false negatives"
• Expansive, non-specific symptom attribution to "chronic Lyme"

---

8. Complications

---

9. Prognosis & Outcomes

Overall Prognosis

Early Disease (EM):

• Cure rate > 95% with appropriate antibiotics [4,19]
• Symptoms resolve within days to weeks
• Antibodies persist for years but do NOT indicate ongoing infection

Early Disseminated Disease:

• Cure rate > 90% with appropriate antibiotics [4,19]
• Facial palsy: 90-95% recover completely; may take 2-6 months
• Lyme carditis: AV block resolves within 1-6 weeks in > 95%

Late Disease:

• Lyme arthritis: Resolution within weeks to months in ~90%; 10% antibiotic-refractory
• Chronic neuroborreliosis: Variable; may have incomplete recovery

Prognostic Factors

Favorable:

• Early diagnosis and treatment
• Limited organ involvement
• Younger age
• Absence of neurological involvement

Unfavorable:

• Delayed diagnosis (> 6 months)
• Extensive neurological involvement
• HLA-DR4 (for antibiotic-refractory arthritis)
• Older age

Long-Term Outcomes [8]

Most patients with treated Lyme disease have excellent long-term outcomes. A subset (10-20%) experience persistent subjective symptoms (PTLDS) but these generally improve over 6-12 months.

Large cohort studies show NO increased long-term mortality or major morbidity from appropriately treated Lyme disease.

Re-infection

• Immunity is NOT lifelong
• Re-infection possible with subsequent tick exposure
• Treat re-infection identically to initial infection

---

10. Prevention & Screening

Personal Protective Measures [9,21]

Avoid Tick Habitats:

• Stay on cleared trails when hiking
• Avoid tall grass and leaf litter
• Greatest risk: woodland, grassland, moorland

Protective Clothing:

• Long sleeves and trousers
• Tuck trousers into socks
• Light-colored clothing (easier to spot ticks)
• Hat

Insect Repellents:

• DEET (20-30%): Apply to skin and clothing
• Permethrin (0.5%): Apply to clothing only (remains effective through multiple washes)
• Reapply per manufacturer instructions

Tick Checks:

• Perform full-body tick checks after outdoor exposure
• Check hidden areas: scalp, axillae, groin, behind knees, behind ears
• Nymphal ticks are 1-2mm (poppy seed size); easily missed
• Prompt removal (less than 24 hours) prevents transmission in most cases

Tick Removal [21]

Correct Technique:

1. Use fine-tipped tweezers
2. Grasp tick as close to skin surface as possible (at mouthparts, NOT body)
3. Pull upward with steady, even pressure (do NOT twist or jerk)
4. Avoid crushing tick body
5. After removal: clean area with alcohol or soap and water
6. Dispose of tick by submersing in alcohol, sealing in bag, or flushing down toilet

Avoid:

• Burning tick
• Applying petroleum jelly, nail polish, or other substances
• Twisting or jerking (may break off mouthparts)

Retained Mouthparts:

• If mouthparts break off in skin, remove with tweezers if possible
• If unable to remove, leave alone; will be expelled naturally
• Clean area and monitor for signs of infection

Prophylactic Antibiotics [19,21]

Single-Dose Doxycycline Prophylaxis:

• Indication: Tick bite with ALL of the following criteria:
  1. Tick identified as Ixodes species
  2. Tick attached ≥36 hours (or engorged)
  3. Prophylaxis can be started within 72 hours of tick removal
  4. Local Lyme disease incidence ≥20%
  5. Doxycycline not contraindicated
• Dose: Doxycycline 200mg single dose PO
• Efficacy: Reduces Lyme disease risk by 87% (NNT = 50)

NOT Routinely Recommended:

• Routine prophylaxis after all tick bites NOT recommended (low transmission risk if less than 36 hours attached; low disease incidence in most areas)
• Amoxicillin prophylaxis NOT effective

Environmental Measures [21]

Landscape Management:

• Clear leaf litter and brush
• Mow lawn regularly
• Create wood chip or gravel barriers between lawn and woodland
• Relocate woodpiles, bird feeders away from house
• Remove rodent habitat (stone walls, dense ground cover)

Acaricides:

• Professional application of tick-killing pesticides may reduce tick populations
• Environmental concerns limit widespread use

Vaccination

• Lyme vaccine (LYMErix) was available 1998-2002 but withdrawn due to poor sales and unfounded safety concerns
• No vaccine currently available
• New vaccines in development (VLA15 in Phase 3 trials)

Screening

• Population screening NOT recommended (low prevalence; high false-positive rate)
• Testing only when clinical suspicion based on symptoms and exposure

---

11. Key Guidelines & Evidence

Major Society Guidelines

IDSA/AAN/ACR Guidelines (2020) [19]:

• Comprehensive evidence-based guidelines for diagnosis and treatment
• Emphasize clinical diagnosis of EM
• Support two-tier serological testing for disseminated disease
• Recommend finite antibiotic courses (10-28 days)
• Explicitly recommend AGAINST prolonged antibiotic therapy for PTLDS

NICE NG95 (2018) [10]:

• UK guideline for Lyme disease diagnosis and management
• Emphasizes clinical diagnosis of EM
• Recommends two-tier testing with ELISA and immunoblot
• Treatment durations: 21 days for most manifestations

European Federation of Neurological Societies (EFNS) [20]:

• Guidelines for European neuroborreliosis
• Highlights differences in clinical presentations between North America and Europe (e.g., Bannwarth syndrome)
• Supports oral doxycycline as alternative to IV ceftriaxone for many neuroborreliosis cases

Landmark Studies

Steere AC, et al. (2016) [1]: Comprehensive review of Lyme borreliosis pathophysiology, clinical features, and management in Nature Reviews Disease Primers.

Wormser GP, et al. (2006) [19]: Original IDSA Lyme disease guidelines establishing evidence-based standards.

Leeflang MM, et al. (2016) [7]: Systematic review and meta-analysis of diagnostic accuracy of Lyme serology in Europe.

Klempner MS, et al. (2001): RCT showing no benefit of prolonged antibiotics for PTLDS (published in NEJM).

---

12. Viva & Exam Preparation

Opening Statement

"Lyme disease is a multi-system infection caused by the spirochaete Borrelia burgdorferi, transmitted by Ixodes ticks. It is the most common vector-borne disease in the Northern Hemisphere with over 300,000 cases annually in the United States. The disease progresses through early localized, early disseminated, and late disseminated stages, affecting skin, nervous system, heart, and joints. Early diagnosis and treatment with antibiotics prevent progression and have excellent cure rates exceeding 95%."

High-Yield Exam Points

Pathognomonic Feature:

• Erythema migrans (expanding annular erythema with central clearing) in endemic area = Lyme disease

Classic Clinical Scenarios:

• Bilateral facial nerve palsy in summer months = neuroborreliosis until proven otherwise
• Young patient with high-degree AV block = consider Lyme carditis
• Migratory oligoarthritis with large knee effusion = Lyme arthritis

Diagnostic Principles:

• EM: clinical diagnosis; do NOT wait for serology
• Disseminated disease: two-tier serological testing (EIA followed by immunoblot)
• Early serology often negative (antibodies take 4-8 weeks)
• Positive serology persists for years; cannot use to assess cure

Treatment Principles:

• Early localized: Doxycycline 100mg BD × 10-21 days
• Neuroborreliosis: Ceftriaxone 2g IV OD × 14-28 days (or oral doxycycline for isolated facial palsy)
• Lyme carditis with high-degree block: Admission, telemetry, ceftriaxone, consider temporary pacing
• Lyme arthritis: Oral antibiotics × 28 days (IV NOT indicated)
• PTLDS: Supportive care; prolonged antibiotics NOT recommended

Common Mistakes

❌ Waiting for serology before treating EM: Treat empirically; early serology often falsely negative

❌ Using serology to assess cure: Antibodies persist for years; clinical assessment only

❌ Ordering Lyme serology for non-specific symptoms in low-probability patients: High false-positive rate; don't screen

❌ Prescribing prolonged antibiotics for PTLDS: No benefit; significant harms; explicitly NOT recommended

❌ Using IV antibiotics for Lyme arthritis without neurological involvement: Oral equally effective; IV unnecessary

❌ Forgetting about Lyme carditis: Rare but potentially life-threatening; always perform ECG if cardiac symptoms

Model Answer: Management of EM

Question: "A 52-year-old woman presents with a 12cm annular erythematous rash on her thigh that has expanded over 5 days. She went hiking in the Lake District 2 weeks ago. How would you manage this?"

Model Answer: "This presentation is highly suggestive of erythema migrans from Lyme disease given the expanding annular morphology, size > 5cm, and exposure history in an endemic area.

I would make a clinical diagnosis of Lyme disease and start empirical antibiotic therapy immediately without waiting for serological confirmation, as antibodies take 4-8 weeks to develop and early testing would likely be falsely negative.

My first-line treatment would be doxycycline 100mg orally twice daily for 10 to 21 days, as this is the most effective agent and also covers Anaplasma, which can be co-transmitted. Alternatives if doxycycline were contraindicated would include amoxicillin 500mg three times daily or cefuroxime axetil 500mg twice daily for 14-21 days.

I would educate the patient about the Jarisch-Herxheimer reaction, which occurs in 7-30% of patients within 24 hours of starting antibiotics, causing transient fever and malaise that resolves spontaneously.

I would advise her to return if symptoms of disseminated disease develop, such as facial weakness, palpitations, syncope, severe headache, or joint swelling. I would also photograph and document the rash characteristics for the medical record.

Serological testing is not needed for diagnosis in this case but could be performed if there were diagnostic uncertainty or for public health surveillance. Follow-up serology after treatment is not useful as antibodies persist for years and do not indicate ongoing infection."

---

13. Patient & Layperson Explanation

What is Lyme Disease?

Lyme disease is an infection you can catch from tick bites. Ticks are tiny spider-like creatures that live in woodland, grassland, and moorland areas. When an infected tick bites you and stays attached for a day or two, it can pass bacteria called Borrelia into your bloodstream.

What are the Symptoms?

Early Signs (First Few Weeks): The most common early sign is a growing red rash called erythema migrans or "bull's-eye rash." It looks like a red ring that gradually expands outward from the tick bite, often with a clearer area in the middle. The rash is usually not painful or itchy and appears 3-30 days after the tick bite.

You might also feel like you have flu: tiredness, headaches, muscle aches, and sometimes a mild fever.

Later Signs (If Untreated): If not treated with antibiotics, the bacteria can spread to other parts of your body:

• Nervous system: Droopy face (facial palsy), severe headaches, nerve pain
• Heart: Irregular or slow heartbeat, dizziness, fainting
• Joints: Swollen, painful joints (especially the knee)

How Serious is It?

When caught early and treated with antibiotics, Lyme disease is very treatable. More than 95% of people make a full recovery. However, if left untreated for months, it can cause long-lasting problems with nerves, heart, or joints.

How is it Treated?

The usual treatment is a 2-3 week course of antibiotic tablets, most commonly doxycycline. If the infection has spread to your nervous system or heart, you might need antibiotics through a drip (intravenous) in hospital.

How Can I Avoid Tick Bites?

When in Woodland or Grassland:

• Wear long sleeves and trousers
• Tuck trousers into socks
• Use insect repellent (containing DEET) on skin and clothes
• Stick to paths; avoid long grass

After Being Outdoors:

• Check your whole body for ticks (they're tiny - about the size of a poppy seed)
• Check hidden areas: scalp, armpits, groin, behind knees
• Get someone to check areas you can't see easily

How Do I Remove a Tick?

If you find a tick attached:

1. Use fine-tipped tweezers
2. Grab the tick as close to your skin as possible (not the body - the head)
3. Pull straight upward with steady pressure
4. Don't twist, squeeze, or burn the tick
5. Clean the bite area with soap and water

Watch for Symptoms: If you develop a rash or feel unwell in the 4 weeks after a tick bite, see your doctor and mention the tick bite.

Common Myths

Myth: "All ticks carry Lyme disease" Truth: Only Ixodes ticks (deer ticks, sheep ticks) spread Lyme disease, and not all of them are infected. In the UK, infection rates vary by region.

Myth: "I need antibiotics every time I get a tick bite" Truth: Not usually. The tick needs to be attached for at least 24 hours to pass on the infection. Quick removal prevents most infections.

Myth: "Lyme disease can't be cured" Truth: Standard antibiotic courses cure over 95% of cases when given appropriately. Long-term antibiotics are not needed and can be harmful.

---

14. References

1. Steere AC, Strle F, Wormser GP, et al. Lyme borreliosis. Nat Rev Dis Primers. 2016;2:16090. doi:10.1038/nrdp.2016.90

2. Radolf JD, Caimano MJ, Stevenson B, Hu LT. Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. Nat Rev Microbiol. 2012;10(2):87-99. doi:10.1038/nrmicro2714

3. Schwartz AM, Kugeler KJ, Nelson CA, et al. Epidemiology of Lyme Disease Diagnoses among Older Adults, United States, 2016-2019. Emerg Infect Dis. 2024;30(9):1846-1854. doi:10.3201/eid3009.231555

4. Schoen RT. Lyme disease: diagnosis and treatment. Curr Opin Rheumatol. 2020;32(3):247-254. doi:10.1097/BOR.0000000000000698

5. Gerstenblith TA, Stern TA. Lyme disease: a review of its epidemiology, evaluation, and treatment. Psychosomatics. 2014;55(5):421-428. doi:10.1016/j.psym.2014.03.004

6. Forrester JD, Mead P. Third-degree heart block associated with lyme carditis: review of published cases. Clin Infect Dis. 2014;59(7):996-1000. doi:10.1093/cid/ciu411

7. Leeflang MM, Ang CW, Berkhout J, et al. The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis. BMC Infect Dis. 2016;16:140. doi:10.1186/s12879-016-1468-4

8. Mac S, da Silva SR, Sander B. The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review. PLoS One. 2019;14(1):e0210280. doi:10.1371/journal.pone.0210280

9. Gray J, Stanek G, Kundi M, Kocianova E. Pathogens transmitted by Ixodes ricinus. Ticks Tick Borne Dis. 2024;15(5):102355. doi:10.1016/j.ttbdis.2024.102355

10. National Institute for Health and Care Excellence. Lyme disease. NICE guideline [NG95]. Published April 2018. https://www.nice.org.uk/guidance/ng95

11. Mead PS. Epidemiology of Lyme disease. Infect Dis Clin North Am. 2015;29(2):187-210. doi:10.1016/j.idc.2015.02.010

12. Kugeler KJ, Schwartz AM, Delorey MJ, Mead PS, Hinckley AF. Estimating the Frequency of Lyme Disease Diagnoses, United States, 2010-2018. Emerg Infect Dis. 2021;27(2):616-619. doi:10.3201/eid2702.202731

13. Brissette CA, Gaultney RA. That's My Story, and I'm Sticking to It-An Update on B. burgdorferi Adhesins. Front Cell Infect Microbiol. 2014;4:41. doi:10.3389/fcimb.2014.00041

14. Sapi E, Kaur N, Anyanwu S, et al. Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi. Infect Drug Resist. 2011;4:97-113. doi:10.2147/IDR.S19201

15. Rauer S, Kastenbauer S, Hofmann H, et al. Guidelines for diagnosis and treatment in neurology - Lyme neuroborreliosis. Ger Med Sci. 2020;18:Doc03. doi:10.3205/000279

16. Karve S, Markowitz M. Lyme Carditis, Tick-Borne Infections and Cardiac Conduction Blocks: An Important Differential to Consider. Cureus. 2020;12(8):e9625. doi:10.7759/cureus.9625

17. Miller JB, Ram S, Archibald LK, Vivino FB. Stages of Lyme Arthritis. J Clin Rheumatol. 2021;27(6S):S258-S262. doi:10.1097/RHU.0000000000001735

18. Branda JA, Strle K, Nigrovic LE, et al. Evaluation of Modified 2-Tiered Serodiagnostic Testing Algorithms for Early Lyme Disease. Clin Infect Dis. 2017;64(8):1074-1080. doi:10.1093/cid/cix043

19. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis. 2021;72(1):e1-e48. doi:10.1093/cid/ciaa1215

20. Ross Russell AL, Dryden MS, Pinto AA, Lovett JK. Lyme disease: diagnosis and management. Pract Neurol. 2018;18(6):455-464. doi:10.1136/practneurol-2018-001998

21. Ost K, Faulkner M, Kulkarni MA. A systematic review of the effectiveness and utility of Lyme disease prevention measures in Canada, the United States, and Europe. BMC Infect Dis. 2025;25(1):31. doi:10.1186/s12879-024-10392-6